PATH vs. CRSP

Last updated Jul 1, 2026

PATH (UiPath Inc.) and CRSP (CRISPR Therapeutics AG) are both stocks. PATH operates in Software - Infrastructure (Technology), while CRSP operates in Biotechnology (Healthcare). Over the past 5 years, PATH returned -30.57%/yr vs -19.02%/yr for CRSP. At a 0.46 correlation, their price movements are largely independent.

Performance

PATH vs. CRSP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in UiPath Inc. (PATH) and CRISPR Therapeutics AG (CRSP). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, PATH achieves a -33.68% return, which is significantly lower than CRSP's 4.00% return.

PATH

• 1D: 1.78%
• 1M: -7.25%
• YTD: -33.68%
• 6M: -34.79%
• 1Y: -15.08%
• 3Y*: -13.11%
• 5Y*: -30.57%
• 10Y*: —

CRSP

• 1D: -3.21%
• 1M: -2.92%
• YTD: 4.00%
• 6M: 2.54%
• 1Y: 12.13%
• 3Y*: -0.96%
• 5Y*: -19.02%
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

PATH vs. CRSP - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
PATH UiPath Inc.	-33.68%	28.95%	-48.83%	95.44%	-70.53%	-34.15%
CRSP CRISPR Therapeutics AG	4.00%	33.23%	-37.12%	54.00%	-46.36%	-37.72%

Correlation

The correlation between PATH and CRSP is 0.27, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.27
Correlation (3Y) Calculated over the trailing 3-year period	0.39
Correlation (5Y) Calculated over the trailing 5-year period	0.46
Correlation (All Time) Calculated using the full available price history since Apr 21, 2021	0.46

The correlation between PATH and CRSP shifts across timeframes, from 0.27 (1 year) to 0.46 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap PATH : $5.74B CRSP : $5.24B
EPS PATH : $0.61 CRSP : -$6.15
PS Ratio PATH : 3.51 CRSP : 1.23K
PB Ratio PATH : 3.01 CRSP : 2.89
Total Revenue (TTM) PATH : $1.67B CRSP : $4.10M
Gross Profit (TTM) PATH : $1.39B CRSP : -$171.17M
EBITDA (TTM) PATH : $115.98M CRSP : -$509.21M

Return for Risk

PATH vs. CRSP — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

PATH

PATH Risk / Return Rank: 34
PATH Sharpe Ratio Rank: 34
PATH Sortino Ratio Rank: 35
PATH Omega Ratio Rank: 34
PATH Calmar Ratio Rank: 34
PATH Martin Ratio Rank: 35

CRSP

CRSP Risk / Return Rank: 50
CRSP Sharpe Ratio Rank: 51
CRSP Sortino Ratio Rank: 51
CRSP Omega Ratio Rank: 49
CRSP Calmar Ratio Rank: 51
CRSP Martin Ratio Rank: 50

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

PATH vs. CRSP - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for UiPath Inc. (PATH) and CRISPR Therapeutics AG (CRSP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	PATH	CRSP	Difference
Sharpe ratio: Return per unit of total volatility	-0.24	0.19	-0.43
Sortino ratio: Return per unit of downside risk	0.09	0.76	-0.67
Omega ratio: Gain probability vs. loss probability	1.01	1.09	-0.08
Calmar ratio: Return relative to maximum drawdown	-0.29	0.29	-0.58
Martin ratio: Return relative to average drawdown	-0.50	0.46	-0.96

PATH vs. CRSP - Sharpe Ratio Comparison

The current PATH Sharpe Ratio is -0.24, which is lower than the CRSP Sharpe Ratio of 0.19. The chart below compares the historical Sharpe Ratios of PATH and CRSP, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

PATH vs. CRSP - Drawdown Comparison

The maximum PATH drawdown since its inception was -88.98%, roughly equal to the maximum CRSP drawdown of -85.11%. Use the drawdown chart below to compare losses from any high point for PATH and CRSP.

Drawdown Indicators

	PATH	CRSP	Difference
Max Drawdown Largest peak-to-trough decline	-88.98%	-85.11%	-3.87%
Max Drawdown (1Y) Largest decline over 1 year	-51.37%	-42.25%	-9.12%
Max Drawdown (3Y) Largest decline over 3 years	-65.10%	-64.91%	-0.19%
Max Drawdown (5Y) Largest decline over 5 years	-86.30%	-79.94%	-6.36%
Current Drawdown Current decline from peak	-87.23%	-74.03%	-13.20%
Average Drawdown Average peak-to-trough decline	-73.85%	-49.35%	-24.50%
Ulcer Index Depth and duration of drawdowns from previous peaks	30.26%	26.26%	+4.00%

Volatility

PATH vs. CRSP - Volatility Comparison

UiPath Inc. (PATH) and CRISPR Therapeutics AG (CRSP) have volatilities of 17.74% and 17.11%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	PATH	CRSP	Difference
Volatility (1M) Calculated over the trailing 1-month period	17.74%	17.11%	+0.63%
Volatility (6M) Calculated over the trailing 6-month period	41.96%	43.84%	-1.88%
Volatility (1Y) Calculated over the trailing 1-year period	63.94%	62.55%	+1.39%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	63.52%	60.52%	+3.00%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	64.03%	64.25%	-0.22%

Dividends

PATH vs. CRSP - Dividend Comparison

Neither PATH nor CRSP has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both PATH and CRSP in my portfolio?

PATH and CRSP have a correlation of 0.27, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, PATH or CRSP?

PATH has higher volatility (17.74%) compared to CRSP (17.11%). In terms of maximum drawdown, PATH dropped -88.98% vs CRSP's -85.11%.

Which has better risk-adjusted returns?

CRSP currently has the higher Sharpe Ratio (0.19 vs -0.24), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.